0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover1813.59%IV-66.22%PremiumAug 30, 2024Expiry Date4.90Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9321Delta0.0104Gamma1.25Leverage Ratio-0.2908Theta0.0001Rho1.17Eff Leverage0.0009Vega
Inovio Pharmaceuticals Stock Discussion
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet